Professor Liu Meilin, director of the Department of Geriatric Medicine at Peking University First Hospital, said that cardiovascular and cerebrovascular disease is an important disease threatening women’s health in China, especially after menopause, the incidence of dyslipidemia in women has increased significantly. Liu Meilin said that dyslipidemia is an important risk factor for cardiovascular and cerebrovascular diseases, and the incidence of cardiovascular and cerebrovascular diseases in women increases rapidly after menopause, and about half of myocardial infarction is related to dyslipidemia.
Professor Liu Meilin, director of the Department of Geriatric Medicine at Peking University First Hospital, said that cardiovascular and cerebrovascular diseases are important diseases threatening women’s health in China, and the incidence of dyslipidemia increases significantly especially after menopause in women. Therefore, postmenopausal women should strengthen their own lipid management.
In order to better care for women’s heart and brain health and pay attention to the increasingly prominent lipid problems of postmenopausal women, the Chinese Expert Consensus on the Management of Dyslipidemia in Postmenopausal Women, initiated by the Working Committee of Female Physicians of the Cardiovascular Physicians Branch of the Chinese Medical Association and other organizations, was released in Beijing recently.
Liu Meilin said that dyslipidemia is an important risk factor for cardiovascular disease, and the incidence of cardiovascular disease in women increases rapidly after menopause, with about half of all myocardial infarctions associated with dyslipidemia.
Professor Ye Ping of the Department of Geriatric Cardiovascular Medicine of the PLA General Hospital, one of the main experts who contributed to the Consensus, pointed out that cholesterol management is particularly important for reducing cardiovascular mortality in China and is of great significance for the maintenance of cardiovascular health in postmenopausal women. Domestic and international guidelines for lipid prevention and control suggest that low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target, and statins are the drugs of choice for LDL-C reduction. Several large-scale clinical trials have demonstrated that statins slow or reverse the progression of atherosclerotic lesions and significantly reduce the prevalence of cardiovascular disease, cardiovascular events and mortality.